A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Summary

This is an open-label, single arm, multicenter study. Subjects will be stratified by histology (clear cell versus non-clear cell). Enrollment of non-clear cell subjects will be limited to ≤ 30% of the entire study population.

Timeline

Start

2011-01

Primary completion

2012-10

Completion

2012-10

Drugs

Indications